English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduAn analysis of national data found that short-term mortality was not impacted for patients with advanced cancers during the shortage of the generic platinum chemotherapy drugs cisplatin and carboplatin that began in early 2023.
Tag: Chemotherapy
Roswell Park Team Identifies Factors That Boost Effectiveness of Immunotherapy in Recurrent Ovarian Cancer
A study led by Roswell Park provides new insight into the complex interactions of the “tumor-immune-gut axis,” and its role in influencing immunotherapy responses in patients with recurrent ovarian cancer. Newly published in Nature Communications, the findings emphasize the role of the patient’s microbiome — the collection of microorganisms in the body —and lay the groundwork for future clinical trials aimed at improving treatment outcomes.
ASH: Monoclonal antibody therapy improves survival in cancer-associated hyper-inflammatory disorder
Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.
Roswell Park Experts Report Insights on CAR T for Follicular Lymphoma, KEYNOTE-667 Combo in Hodgkin Lymphoma
The results of two important lymphoma studies led by experts at Roswell Park Comprehensive Cancer Center will be presented during oral abstract sessions this morning at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California. Lymphoma is a type of blood cancer that causes white blood cells called lymphocytes to grow out of control and behave abnormally.
MD Anderson Research Highlights: ASH 2024 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This special edition features upcoming oral presentations by MD Anderson researchers at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, providing new insights and advances in hematological malignancies and diseases. All ASH content from MD Anderson can be found at MDAnderson.org/ASH.
Moffitt Study Shows How Cancer Cell Death May Harm the Immune System and Promote Tumor Growth
A new study has uncovered an unexpected way cancer cells can escape the immune system, making it harder for treatments to work. The study, published in Cancer Cell, explains how a type of cancer cell death can actually make tumors grow faster by turning off the immune system’s ability to fight the cancer.
Treatment advances, predictive biomarkers stand to improve bladder cancer care
Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to a New England Journal of Medicine editorial published by Matthew Milowsky, MD, FASCO, a bladder cancer expert at UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center.
Data detectives strike back at deadly childhood cancer
Neuroblastoma is a rare and aggressive form of childhood cancer. Striking in infancy, it shatters what should be a family’s time of joy, shifting it to a fight for survival. While the search for a cure continues, researchers at the University of South Australia are striving to decode the causes of neuroblastoma to inform new, less toxic treatment strategies for young patients.
In Landmark Study, Immunotherapy Boosts Survival of Advanced Hodgkin Lymphoma
A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92 percent, suggesting a new standard therapy for the disease. The New England Journal of Medicine published the innovative clinical trial results this week.
Breast Cancer Awareness: Filmmaker Uses Art in Healing
After her stage 4 breast cancer diagnosis, independent filmmaker Kailee McGee decided not to leave her director’s chair. Instead, she leaned in and produced an award-winning short film about her experience.
Dual immunotherapy plus chemotherapy benefits specific subset of patients with lung cancer
Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more likely to benefit from adding the immunotherapy tremelimumab to a combination of durvalumab plus chemotherapy to overcome treatment resistance typically seen in this patient population.
Dana-Farber Cancer Institute delivers ‘simple immediate impact’ to patient comfort using weighted blankets
Weighted blankets are available to patients receiving infusions at all Dana-Farber locations as the result of a project led by staff nurse Cheri Hermann, BSN, RN, OCN. The initiative dates to March 2020, when she observed heightened anxiety in patients whose loved ones were unable to accompany them to appointments during the COVID-19 pandemic.
Gut Microbiome Health Tech Innovator, Ixcela Launches Virtual Clinic to Ease Cancer Symptoms After Landmark Roper St. Francis Healthcare Pilot
In recognition of Breast Cancer Awareness month, Ixcela, The Internal Fitness™ Company, in collaboration with Roper St. Francis Healthcare, today announced the Ixcela Cancer Support Program.
Channeling Challenge Into Community: Hunter’s Story
Hunter doesn’t remember much from his time at Children’s Hospital Los Angeles, but more than a decade later, one small moment has stuck with him in multiple ways.A blonde woman asks him: “She’d hold up an array of ChapSticks,” Hunter explains, “blueberry, strawberry, green apple, root beer float and chocolate.”
Elle Macpherson says she refused chemotherapy after breast cancer diagnosis. Here’s what oncologists think.
After being diagnosed with breast cancer seven years ago, Elle Macpherson made a controversial choice: She refused chemotherapy, the model has revealed in her new memoir, Elle: Life, Lessons, and Learning to Trust Yourself. Macpherson did undergo a lumpectomy — surgery to remove…
Immunotherapy Before and After Lung Cancer Surgery Reduces Death Risk, Disease Recurrence
People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to a new analysis by Johns Hopkins Kimmel Cancer Center investigators.
MD Anderson Research Highlights for September 4, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Botanical medicine reduces rectal cancer treatment side effects that can sideline surgeries
Ancient Chinese traditional medicine significantly reduces the side effects of rectal cancer treatments that, in some patients, can be so toxic that treatment must be paused, or stopped, which diminishes its effectiveness.
FAU Researcher Receives Grant to Personalize Radiation Therapy for Cancer
While chemotherapy has advanced in personalization, personalized radiation therapy for cancer remains underdeveloped. A new project will use AI, in particular, deep reinforcement learning, to analyze multimodal data, and enhance cancer characterization and treatment to ultimately improve patient outcomes. Using personal health data, genetic information about the tumor, and patient treatment and follow-up data, digital twins will simulate diagnoses and treatment options to help physicians choose the most effective treatments and monitor responses over time.
MD Anderson Research Highlights for July 24, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Travel Distance Does Not Affect Overall Survival in Patients with Appendiceal Adenocarcinoma Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Abstract Introduction Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a potentially curative approach for appendiceal cancer (AC) with peritoneal dissemination and is most often employed at tertiary referral centers. Regionalization may provide geographic barriers to care for vulnerable patients.…
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
Intensity Therapeutics, Inc. , a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer therapies intended to kill tumors directly and increase immune system recognition of cancers, announces that the first U.S. patient has been dosed in the Company’s Phase 3 study to treat metastatic sarcoma (NCT06263231).
New Treatment for Uterine Cancer Receives FDA Approval
The U.S. Food & Drug Administration has approved use of a new treatment option for patients with advanced or recurring uterine cancer. The news comes after completion of the first Phase III trial to statistically evaluate an anti-PD1 immunotherapy, called…
Chemotherapy disrupts gut microbiome in patients with breast cancer
“For the first time ever, our Intelligut Study found that the gut microbiome has been implicated in cognitive side effects of chemotherapy in humans,” said senior author Leah Pyter, associate professor of psychiatry and neuroscience with The Ohio State University Wexner Medical Center and College of Medicine.
MD Anderson Research Highlights for June 5, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Emma Guttman-Yassky, MD, PhD, Receives High Honor at European Academy of Allergy and Clinical Immunology
The Paul Ehrlich Award for Experimental Research recognizes scientists who have revolutionized the understanding of allergic diseases and immunological mechanisms.
Trilaciclib use for prevention of hematological adverse events in chemotherapy: A meta-analysis of real-world studies and clinical trials
Background: Trilaciclib, a cyclin-dependent kinase (CDK)-4 and -6 inhibitor, is the only FDA-approved agent that preemptively protects hematopoietic stem cells from chemotherapy-induced myelosuppression (CIM) without compromising efficacy. It transiently arrests hematopoietic stem cells in the G1 phase, thus temporarily blocking progression…
Study Results: Subsequent Chemotherapy May Increase Risk of Joint Infection for Patients with Joint Replacements
Researchers at Sinai Hospital of Baltimore have found a possible relationship between receiving chemotherapy within a year of total joint replacement surgery and increased incidence of infection in the replaced joint. Findings published this month in the Archives of Orthopaedic and Trauma Surgery.
Donepezil Does Not Improve Chemotherapy-Related Cognitive Impairment
Researchers at Wake Forest University School of Medicine conducted a Phase III randomized, placebo-controlled trial to test donepezil, a cognitive-enhancing medicine used in the treatment of Alzheimer’s disease. The research team found that donepezil did not improve memory or other cognitive functions in survivors with cancer-related cognitive impairment.
New gene signature could transform immunotherapy for gastrointestinal cancers
A recent study in gastrointestinal (GI) cancer research reveals a promising advancement in predicting patient responses to immune checkpoint inhibitor (ICI) therapy. The newly developed DNA damage response-related immune activation (DRIA) signature could serve as a groundbreaking biomarker, providing valuable guidance for ICI therapy decisions.
Timing of Both Fasting and Meals Affects Degree of DNA Damage to Small Intestine Caused by Chemotherapy
Article title: Mechanisms driving fasting-induced protection from genotoxic injury in the small intestine Authors: Kali Deans-Fielder, Timothy Wu, Thanh Nguyen, Sarah To, Yang-Zhe Huang, Steven J. Bark, Jason C. Mills, Noah F. Shroyer From the authors: “Our results also showed…
MD Anderson Research Highlights for April 12, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Chemotherapy in Pediatric Mice Linked to Long-term Muscle Defects
Rockville, Md. (April 3, 2024)—Recent progress in research related to cancer treatment has made it possible for children with cancer to survive into adulthood. However, the long-term physiological consequences of chemotherapy are understudied. This study investigated persistent musculoskeletal consequences of…
Yale Cancer Center Experts, Scientists to Share Vision and Research at Leading Conference
The five-day session (April 5-10), themed as “Inspiring Science. Fueling Progress. Revolutionizing Care,” will include new findings from Yale Cancer Center researchers.
Answers from an Expert: Esophageal Cancer
Benjamin Medina, MD, thoracic surgeon in the Lung/Thoracic Oncology Program at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, answers common questions about esophageal cancer during esophageal cancer awareness month.
Medical and Psycho-Oncologists Available for Interviews
If you are seeking an expert to discuss chemotherapy and coping with potential side effects following a cancer diagnosis, Dr. Mikkael Sekeres is available. We also have available psycho-oncologists who can discuss the psychosocial aspects of dealing with the shock…
New treatment for a rare and aggressive cancer improves survival rates in breakthrough clinical trial
An innovative treatment significantly increases the survival of people with malignant mesothelioma, a rare but rapidly fatal type of cancer with few effective treatment options, according to results from a clinical trial led by Queen Mary University of London.
Researchers Discover Why One Type of Chemotherapy Works Best in Bladder Cancer
Tisch Cancer Institute researchers discovered that a certain type of chemotherapy improves the immune system’s ability to fight off bladder cancer, particularly when combined with immunotherapy, according to a study published in Cell Reports Medicine in January.
Johns Hopkins Medicine Researchers Create Machine Learning Model To Calculate Chemotherapy Success In Patients With Osteosarcoma
A research team at Johns Hopkins Medicine has created and trained a machine learning model to calculate percent necrosis (PN) — or, what percentage of a tumor is “dead” and no longer active — in patients with osteosarcoma, a type of bone cancer. The model’s calculation was 85% correct when compared to the results of a musculoskeletal pathologist.
Better use of existing drugs increases cervical cancer survival and reduces recurrence
A course of treatment with existing drugs prior to chemoradiation led to a 35% reduction in the risk of death or return of cancer, in trial results presented by researchers from UCL and UCLH.
MD Anderson Research Highlights: ESMO 2023 Special Edition
This special edition features upcoming oral presentations by MD Anderson researchers at the 2023 European Society for Medical Oncology (ESMO) Congress focused on clinical advances across a variety of cancer types.
RUDN Biochemists Found How to Weaken Cancer Cells
Biochemists from RUDN University described how to prevent cancer cells from becoming resistant to chemotherapy drugs. Having determined the resistance mechanism, biochemists selected a drug that can slow down it.
Breast Cancer at 30?
Amanda Butler and Isabella Bugatti, both just entering their 30s, were blindsided by a diagnosis that is on the rise among women their age: breast cancer.
MD Anderson Research Highlights for October 4, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at MD Anderson include a computer game that helps breast cancer survivors improve symptoms of peripheral neuropathy, a publicly available single-cell atlas of CD19 chimeric antigen receptor (CAR) T cells, new targets for TP53-mutant acute myeloid leukemia (AML), a preclinical target for preventing chemobrain, a blood test to help identify patients at higher risk of developing pancreatic cancer, and genomic insights to predict the risk of outcomes in patients with bone cancer.
Advanced Bladder Cancer Patients Could Keep Their Bladder Under New Treatment Regime, Clinical Trial Shows
Mount Sinai investigators have developed a new approach for treating invasive bladder cancer without the need for surgical removal of the bladder, according to a study published in Nature Medicine in September.
Researchers pioneer safe chemotherapy methods for treating bacterial infections
Antibiotic resistant bacteria are a threat to human lives, and yet the development of new drugs to treat bacterial infections is slow.
St. Jude shows cancer resistance protein can have its cake and eat it too
Scientists at St. Jude Research Hospital unravel the mechanisms behind a key culprit in chemotherapy resistance.
Research sheds new light on gene therapy for blood disorders
A study shows new steps toward more patients getting gene therapy
Study Offers Guidance for Improving Access to Oncology Drug Treatments in Sub-Saharan Africa
Botswana-Rutgers Partnership for Health researchers review treatments that could improve outcomes for patients in a region where cancer rates are rising significantly.
MD Anderson Research Highlights for June 7, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.